<h2 dir="ltr">Liver Fibrosis</h2>
Liver fibrosis is the buildup of scar tissue in the liver due to chronic liver damage from conditions like hepatitis, alcohol use, or non-alcoholic fatty liver disease (NAFLD). It can progress to cirrhosis if untreated. Early stages may be symptomless; management focuses on treating the underlying cause to prevent further damage.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total Liver Fibrosis Diagnosed Prevalent Cases
</li>
<li dir="ltr" aria-level="1">
Liver Fibrosis Severity-specific Diagnosed Prevalent Cases
</li>
<li dir="ltr" aria-level="1">
Total Liver Fibrosis Diagnosed Prevalent Cases (&ge;F2 Stage) in MASH
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/liver-fibrosis-epidemiology-forecast">Liver Fibrosis Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2023, there were an estimated 8 million diagnosed prevalent cases of liver fibrosis in the 7MM, expected to rise by 2034.
</li>
<li dir="ltr" aria-level="1">
The US accounted for the highest number, with ~4 million cases, projected to increase further.
</li>
<li dir="ltr" aria-level="1">
Among EU4 and the UK, Germany led with ~770K cases, followed by Italy (~620K), France (~520K), and Spain (~360K).
</li>
<li dir="ltr" aria-level="1">
Japan reported ~1.2 million cases in 2023, also expected to grow by 2034.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/liver-fibrosis-market">Liver Fibrosis Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2023, the liver fibrosis treatment market size in the 7MM was approximately USD 1.8 billion, with growth expected through 2034.
</li>
<li dir="ltr" aria-level="1">
The US alone accounted for ~USD 1.3 billion in 2023, driven by rising cases and upcoming therapies.
</li>
<li dir="ltr" aria-level="1">
REZDIFFRA (resmetirom) is projected to generate around USD 2.5 billion in revenue by 2034 across the 7MM.
</li>
</ul>
<h3 dir="ltr">Liver Fibrosis Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Increasing cases of conditions like NASH, hepatitis, and alcohol-related liver disease are driving the demand for liver fibrosis treatments.
</li>
<li dir="ltr" aria-level="1">
Advancements in antifibrotic drugs and targeted treatments&mdash;such as REZDIFFRA (resmetirom)&mdash;are expected to transform the treatment landscape and boost market growth.
</li>
</ul>
<h3 dir="ltr">Liver Fibrosis Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Despite a growing pipeline, there are currently limited approved drugs specifically for liver fibrosis, restricting treatment options.
</li>
<li dir="ltr" aria-level="1">
Liver fibrosis often progresses silently, leading to late-stage diagnosis and delayed treatment initiation.
</li>
</ul>
<h3 dir="ltr">Liver Fibrosis Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
Efruxifermin (EFX)
</li>
<li dir="ltr" aria-level="1">
Denifanstat (TVB-2640)
</li>
<li dir="ltr" aria-level="1">
Survodutide (BI 456906)
</li>
<li dir="ltr" aria-level="1">
Pegozafermin (BIO89-100)
</li>
<li dir="ltr" aria-level="1">
Lanifibranor (IVA337)
</li>
<li dir="ltr" aria-level="1">
Aramchol
</li>
<li dir="ltr" aria-level="1">
WEGOVY (semaglutide 2.4 mg)
</li>
<li dir="ltr" aria-level="1">
VK2809 (TR&szlig; Agonist)
</li>
<li dir="ltr" aria-level="1">
Rencofilstat (CRV431)
</li>
<li dir="ltr" aria-level="1">
Ervogastat (DGAT2i; PF-06865571) + Clesacostat (ACCi; PF-05221304)
</li>
<li dir="ltr" aria-level="1">
Berberine ursodeoxycholate (HTD1801)
</li>
<li dir="ltr" aria-level="1">
Efimosfermin alfa (formerly BOS-580)
</li>
<li dir="ltr" aria-level="1">
HU6
</li>
<li dir="ltr" aria-level="1">
LPCN 1144
</li>
<li dir="ltr" aria-level="1">
ALG-055009
</li>
<li dir="ltr" aria-level="1">
MN-001 (tipelukast)
</li>
<li dir="ltr" aria-level="1">
Icosabutate
</li>
<li dir="ltr" aria-level="1">
Tirzepatide (LY3298176)
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/liver-fibrosis-pipeline-insight">Liver Fibrosis Key Players</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Akero Therapeutics
</li>
<li dir="ltr" aria-level="1">
Sagimet Biosciences
</li>
<li dir="ltr" aria-level="1">
Boehringer Ingelheim
</li>
<li dir="ltr" aria-level="1">
Zealand Pharma
</li>
<li dir="ltr" aria-level="1">
89bio
</li>
<li dir="ltr" aria-level="1">
Inventiva Pharma
</li>
<li dir="ltr" aria-level="1">
Galmed Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Novo Nordisk A/S
</li>
<li dir="ltr" aria-level="1">
Viking Therapeutics
</li>
<li dir="ltr" aria-level="1">
Hepion Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Pfizer
</li>
<li dir="ltr" aria-level="1">
HighTide Biopharma
</li>
<li dir="ltr" aria-level="1">
Boston Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Rivus Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Lipocine
</li>
<li dir="ltr" aria-level="1">
Aligos Therapeutics
</li>
<li dir="ltr" aria-level="1">
MediciNova
</li>
<li dir="ltr" aria-level="1">
NorthSea Therapeutics
</li>
<li dir="ltr" aria-level="1">
Eli Lilly
</li>
</ul>
And others.
<a href="https://www.delveinsight.com/">Liver Fibrosis</a>

‘Liver Fibrosis Market

‘Liver Fibrosis Infograhics

Liver Fibrosis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape